EcoDrugPlus

Bcl2 Like 1

Ensembl ID : ENSPNYG00000009301
Gene Symbol: BCL2L1
3 Cross references
226 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSPNYG00000001228
Gene Symbol: BCL2L10
3 Cross references
128 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSPNYG00000013371
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSPNYG00000007888
Gene Symbol: BCR
3 Cross references
196 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSPNYG00000005928
Gene Symbol: LOC102212172
3 Cross references
207 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSPNYG00000009160
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSPNYG00000004352
Gene Symbol: LOC102198680
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSPNYG00000003421
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSPNYG00000001403
Gene Symbol: CXCR1
1 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSPNYG00000016443
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSPNYG00000014343
Gene Symbol: LOC102213746
2 Cross references
359 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSPNYG00000001660
Gene Symbol: LOC102208462
3 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).